I'm passionate about a biopharmaceutical value transformation that leads industry to lasting engagements with patients, payors and providers.
Ulrich Neumann, MBA MSc MA BSc BA founded Pharmvivo as a thought leadership network in 2016 to bring a new level of collaboration to members of the biopharma industry. He currently serves as Director for Market Access Scientific and External Strategy for Janssen, the Pharmaceutical Companies of Johnson & Johnson. Views expressed on his blog and social media reflect his personal opinions and are not coordinated with, and do necessarily represent those of his employer or any of the organizations he's affiliated with.
Prior to his career at Johnson & Johnson, Ulrich was Senior US Director at Certara, where he led the Access and Commercial Strategy team in New York. Certara is a drug development strategy and software platform which listed on Nasdaq at over $5 billion in 2020. With a dual background in business and public administration, Ulrich engaged pharma developers on reimbursement and commercial strategy projects, while also serving as Certara lead for commercial due diligences with private equity clients on product financing to the tune of $2-3 billion annually.
Ulrich's commercial experience lies in value messaging, defining product strategy, pricing and financing. The founder of several entrepreneurial ventures, he joined Certara through the acquisition of Analytica Laser, a leading population health intelligence consultancy with offices in seven countries. At Analytica Laser Ulrich was member of the global management team, in charge of the company's global positioning, reporting directly to the Group Chairman. He previously served as the US Managing Director of a global pharmaceutical networking platform (now part of Thomson Reuters) and worked on go-to-market projects for over ten years, leading multimillion $ P&Ls and cross-functional academic/commercial teams in Europe and the US. Trained in public and corporate affairs, he managed strategy projects for multi-national clients in the health, bottled water, energy, and defense industries, serving at agencies such as Advice Partners (PRGS) and Hill & Knowlton (WPP), at the President of the EU Parliament as well as on projects funded by France’s Ministry of Foreign Affairs. A frequent expert contributor and conference speaker, Ulrich also launched the “The Market Access Radar”, a broadcast and global intelligence product on current pharma policy and reimbursement topics.
Ulrich holds an MBA from the Business School at Imperial College London, an MSc from the London School of Economics and an MA from the University of Southern California, Annenberg School and Marshall School of Business. His undergraduate degrees are in Public Administration (BSc) and Multi-level Governance (BA). The author of two books, he has published various trade articles, whitepapers, reports, and posters on critical pharma and managed care topics. Ulrich is frequently speaking at industry conferences such Reuters Events, CBI, World Congress or as the keynote speaker at 'eyeforpharma Philadelphia' in 2016. As time allows he enjoys giving lectures and graduate seminars, such as recently on clinical trial innovation at Rutgers University Irvine Center. A member of AMCP, AMBA, DIA and ISPOR, he sits on the Health Economics Interest Group at Academy Health and is a nominated Fellow of the Royal Society of Arts and Commerce since 2014.